From 965afb6985e5d3cafe19db1979bd4a11cc83a33c Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 14:55:19 +0000 Subject: [PATCH] extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...-cardiovascular-and-metabolic-endpoints.md | 6 ++++ ...ients-undermining-chronic-use-economics.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...mployer-cost-savings-cancer-reduction.json | 32 +++++++++++++++++++ ...-employer-cost-savings-cancer-reduction.md | 16 +++++++++- 6 files changed, 71 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ff0765e39..16e165008 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics. + +### Additional Evidence (challenge) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's 192K patient analysis shows medical cost growth drops to 2% after 12 months for GLP-1 users vs. 6% for non-users, with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This challenges the 'inflationary through 2035' thesis for long-term risk-bearers—the data suggests net savings emerge within 18-30 months for adherent users in capitated systems, though short-term payers and non-adherent populations still face inflation. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index b3b29624c..1fb18930e 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -48,6 +48,12 @@ Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatit FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary endpoints in a study designed for kidney outcomes, supporting the multi-organ protection thesis. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's 192K patient analysis found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations in women and 26% in men, with the sex differential suggesting larger cardiovascular benefits for women. This adds to the multi-organ protection thesis by showing substantial cardiovascular risk reduction in real-world commercial populations, not just clinical trials. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..9500d9f55 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon data shows adherence is the binding variable for GLP-1 effectiveness—the 80%+ adherent cohort shows dramatically stronger effects across all outcomes (9 percentage point lower cost growth vs. 6 points for all diabetes users; 7 points vs. 3 for weight loss users). This confirms that low persistence rates directly undermine the cost-effectiveness case because benefits scale non-linearly with adherence. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa03417..733ab8ed3 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward employed, insured populations. The finding that benefits require 80%+ adherence indirectly supports the affordability thesis—populations with coverage gaps or cost-sharing barriers cannot achieve the adherence levels needed for cost-effectiveness. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json new file mode 100644 index 000000000..1aace1702 --- /dev/null +++ b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-medical-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-women.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 0caf70348..e7473751a 100644 --- a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,9 +7,13 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,13 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary. flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"] + + +## Key Facts +- Aon analyzed commercial health claims data from 192,000+ GLP-1 users in U.S. employer-sponsored plans +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users +- After 12 months: medical costs grow 2% vs. 6% for non-users +- For diabetes indication: medical cost growth 6 percentage points lower at 30 months; 9 points lower with 80%+ adherence +- For weight loss indication: cost growth 3 points lower at 18 months; 7 points lower with consistent use +- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence +- Adherent users (80%+): 47% fewer MACE hospitalizations in women, 26% in men